Across TCGA pan-cancer cohorts, PFDN6 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PFDN6 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PFDN6 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PFDN6 expression acts as an unfavorable survival marker.

LUAD are the cancer types where PFDN6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.098	0.791	<.001	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: PFDN6 tumor-vs-normal RNA expression · all PFDN6 data types